Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MVT-1075 + MVT-5873 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVT-1075 | MVT-1075 is a radiolabeled IgG1 antibody that binds to the sialyl Lewis A epitope of CA19-9 and is conjugated to a bifunctional chelator, which may result in tumor growth inhibition and tumor regression (AACR 2017, Abstract nr5204). | |||
MVT-5873 | HuMab 5B1|HuMab-5B1|BNT321 | MVT-5873 (HuMab-5B1) is an IgG1 antibody that binds to the sialyl Lewis A epitope of CA19-9, which may result in antitumor activity including tumor growth inhibition (Cancer Res 2016;76(24 Suppl):Abstract nr A73, PMID: 32399263). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03118349 | Phase I | MVT-1075 + MVT-5873 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | Terminated | USA | 0 |